Regeneron Pharmaceuticals, Inc. (REGN) Balance Sheet
As of 2026-06-30 (10-Q), Regeneron Pharmaceuticals, Inc. (REGN) reported total assets of $41.7B, total liabilities of $10.0B and shareholders' equity of $31.7B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $2.5B. Long-term debt: $2.0B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
REGNRegeneron Pharmaceuticals, Inc.Follow REGN — free
—
Price chart with a free account
- Market cap
- 82.9B
- P/E TTM
- 19.9
- Dividend yield
- 0.5%
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
| Line | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.11 | 0.48 | 0.23 | 0.54 | 0.65 | 0.81 | 0.54 | 0.81 | 1.47 | 1.62 | 2.19 | 2.89 | 3.11 | 2.73 | 2.49 | 3.12 | 2.46 | |
| Short-term investments | 0.14 | 0.04 | 0.08 | 0.16 | 0.25 | 0.24 | 0.50 | 0.60 | 1.34 | 1.60 | 1.39 | 2.81 | 4.64 | 8.11 | 6.52 | 5.49 | 5.54 | |
| Receivables | 0.00 | 0.03 | 0.59 | 0.79 | 0.74 | 1.15 | 1.34 | 1.54 | 1.72 | 2.10 | 4.11 | 6.04 | 5.33 | 5.67 | 6.21 | 5.74 | 6.57 | |
| Inventory | 0.00 | 0.02 | 0.03 | 0.07 | 0.13 | 0.24 | 0.40 | 0.73 | 1.15 | 1.42 | 1.92 | 1.95 | 2.40 | 2.58 | 3.09 | 3.20 | 3.08 | |
| Current assets | 0.36 | 0.67 | 1.21 | 1.80 | 2.08 | 2.92 | 3.18 | 4.34 | 6.45 | 7.69 | 9.78 | 14.01 | 15.88 | 19.48 | 18.66 | 18.02 | 18.45 | |
| Total assets | 1.09 | 1.32 | 2.08 | 2.95 | 3.84 | 5.61 | 6.97 | 8.76 | 11.73 | 14.81 | 17.16 | 25.43 | 29.21 | 33.08 | 37.76 | 40.56 | 41.73 | |
| Current liabilities | 0.11 | 0.15 | 0.16 | 0.30 | 0.65 | 0.81 | 1.24 | 1.14 | 1.44 | 2.10 | 2.70 | 3.93 | 3.14 | 3.42 | 3.94 | 4.37 | 5.53 | |
| Long-term debt | — | — | — | — | — | — | — | — | — | 0.00 | 1.98 | 1.98 | 1.98 | 1.98 | 1.98 | 1.99 | 1.99 | |
| Short-term debt | — | — | — | 0.00 | 0.01 | — | — | — | — | 0.00 | — | — | — | — | — | — | — | |
| Total liabilities | 0.56 | 0.84 | 0.84 | 1.00 | 1.29 | 1.95 | 2.52 | 2.62 | 2.98 | 3.72 | 6.14 | 6.67 | 6.55 | 7.11 | 8.41 | 9.30 | 10.02 | |
| Shareholders' equity | 0.53 | 0.49 | 1.26 | 1.96 | 2.55 | 3.65 | 4.45 | 6.14 | 8.76 | 11.09 | 11.03 | 18.77 | 22.66 | 25.97 | 29.35 | 31.26 | 31.71 |
USD billions · SEC XBRL
Regeneron Pharmaceuticals, Inc. — questions
- How much cash does Regeneron Pharmaceuticals, Inc. have?
- $2.5B in cash and cash equivalents as of 2026-06-30.
- How much debt does Regeneron Pharmaceuticals, Inc. have?
- $2.0B of long-term debt as of 2026-06-30.
- What are Regeneron Pharmaceuticals, Inc.'s total assets?
- $41.7B as of 2026-06-30.
- What is Regeneron Pharmaceuticals, Inc.'s shareholders' equity?
- $31.7B as of 2026-06-30.
Every figure on this page comes from Regeneron Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.